Cargando…
The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis
OBJECTIVES: The rate of early neurological deterioration (END) occurring after thrombolytic therapy is controversial. To explore a more precise estimation of the rate, a meta‐analysis was conducted in the present study. METHODS: The relevant studies were identified by searching PubMed, EMBASE, and C...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379592/ https://www.ncbi.nlm.nih.gov/pubmed/30632308 http://dx.doi.org/10.1002/brb3.1210 |
_version_ | 1783396121161236480 |
---|---|
author | Hou, Xiaowen Chen, Wanli Xu, Haibin Zhu, Zhi Xu, Yuanyuan Chen, Huisheng |
author_facet | Hou, Xiaowen Chen, Wanli Xu, Haibin Zhu, Zhi Xu, Yuanyuan Chen, Huisheng |
author_sort | Hou, Xiaowen |
collection | PubMed |
description | OBJECTIVES: The rate of early neurological deterioration (END) occurring after thrombolytic therapy is controversial. To explore a more precise estimation of the rate, a meta‐analysis was conducted in the present study. METHODS: The relevant studies were identified by searching PubMed, EMBASE, and Cochrane Collaboration Database up to June 2018. The definition of END was prespecified according to the most commonly used definition: ≥4‐point increase in National Institutes of Health Stroke Scale between admission and 24 hr. The meta‐analysis was performed by using the STATA 12. RESULTS: Eleven studies with a total of 3,539 subjects, including 373 patients with END and 3,166 patients without END, were collected. The pooled analysis showed that the rate of END occurring after thrombolytic therapy was about 11.0% (95% CI: 7.8%–14.3%). Subgroup analysis by continent showed that the rate of END occurring after thrombolytic therapy of patients in Asia (15.9%, 95% CI: 7.4%–24.5%) was higher than in Europe (7.6%, 95% CI: 4.9%–10.3%) and in North America (11.8%, 95% CI: 8.5%–15.0%). Subgroup analysis by onset to treatment time (OTT) displayed that the rate of END occurring after thrombolytic therapy was 5.4% (95% CI: 1.2%–9.5%), 15.6% (95% CI: 9.6%–21.5%), and 18.5% (95% CI: 11.2%–25.8%) for the patients whose OTT ≤120.0 min, from 120.1 to 179.9 min, from 180.0 to 270.0 min, respectively. CONCLUSION: The rate of END occurring after thrombolytic therapy is about 11.0%. This finding may provide a scientific reference for researchers to evaluate the efficacy and safety of thrombolytic therapy. |
format | Online Article Text |
id | pubmed-6379592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63795922019-02-28 The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis Hou, Xiaowen Chen, Wanli Xu, Haibin Zhu, Zhi Xu, Yuanyuan Chen, Huisheng Brain Behav Original Research OBJECTIVES: The rate of early neurological deterioration (END) occurring after thrombolytic therapy is controversial. To explore a more precise estimation of the rate, a meta‐analysis was conducted in the present study. METHODS: The relevant studies were identified by searching PubMed, EMBASE, and Cochrane Collaboration Database up to June 2018. The definition of END was prespecified according to the most commonly used definition: ≥4‐point increase in National Institutes of Health Stroke Scale between admission and 24 hr. The meta‐analysis was performed by using the STATA 12. RESULTS: Eleven studies with a total of 3,539 subjects, including 373 patients with END and 3,166 patients without END, were collected. The pooled analysis showed that the rate of END occurring after thrombolytic therapy was about 11.0% (95% CI: 7.8%–14.3%). Subgroup analysis by continent showed that the rate of END occurring after thrombolytic therapy of patients in Asia (15.9%, 95% CI: 7.4%–24.5%) was higher than in Europe (7.6%, 95% CI: 4.9%–10.3%) and in North America (11.8%, 95% CI: 8.5%–15.0%). Subgroup analysis by onset to treatment time (OTT) displayed that the rate of END occurring after thrombolytic therapy was 5.4% (95% CI: 1.2%–9.5%), 15.6% (95% CI: 9.6%–21.5%), and 18.5% (95% CI: 11.2%–25.8%) for the patients whose OTT ≤120.0 min, from 120.1 to 179.9 min, from 180.0 to 270.0 min, respectively. CONCLUSION: The rate of END occurring after thrombolytic therapy is about 11.0%. This finding may provide a scientific reference for researchers to evaluate the efficacy and safety of thrombolytic therapy. John Wiley and Sons Inc. 2019-01-10 /pmc/articles/PMC6379592/ /pubmed/30632308 http://dx.doi.org/10.1002/brb3.1210 Text en © 2019 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Hou, Xiaowen Chen, Wanli Xu, Haibin Zhu, Zhi Xu, Yuanyuan Chen, Huisheng The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis |
title | The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis |
title_full | The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis |
title_fullStr | The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis |
title_full_unstemmed | The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis |
title_short | The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis |
title_sort | rate of early neurological deterioration occurring after thrombolytic therapy: a meta‐analysis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379592/ https://www.ncbi.nlm.nih.gov/pubmed/30632308 http://dx.doi.org/10.1002/brb3.1210 |
work_keys_str_mv | AT houxiaowen therateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis AT chenwanli therateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis AT xuhaibin therateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis AT zhuzhi therateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis AT xuyuanyuan therateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis AT chenhuisheng therateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis AT houxiaowen rateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis AT chenwanli rateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis AT xuhaibin rateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis AT zhuzhi rateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis AT xuyuanyuan rateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis AT chenhuisheng rateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis |